+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07110584

Phase 12 Study of MDX2004 Intravenous Treatment in Adults with Advanced Tumors

Led by ModeX Therapeutics, An OPKO Health Company · Updated on 2026-03-05

235

Participants Needed

6

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, and anti-tumor activity of MDX2004 in adults with advanced or metastatic tumors. This Phase 12 clinical study aims to find the appropriate dose and assess the effects of MDX2004 when given as an intravenous infusion. The study includes participants with various advanced tumors to better understand how the treatment works in this population. Participants will receive MDX2004 through intravenous infusions during different study parts dose escalation, indication optimization, dose optimization, and dose expansion. Each part involves receiving MDX2004 at different dose levels or the recommended Phase 2 dose. The treatment is administered under medical supervision across multiple centers, with dosing schedules tailored to each study part. During the study, participants will undergo evaluations including monitoring for adverse events from the start of treatment until 90 days after the last dose. Researchers will measure tumor response rates and pharmacokinetics such as blood levels of MDX2004 over approximately six months. Other assessments include immunogenicity and disease control measures. Participant safety and treatment effects will be closely followed throughout the treatment and follow-up periods, lasting up to several months.

CONDITIONS

Brief Title

Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors

Research Team

M

ModeX Therapeutics, An OPKO Health Company

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here